For the first time in years, the data on national drug overdose deaths offers a glimpse at progress. According to the Centers for Disease Control and Prevention, there was a 14% decline in U.S. drug overdose deaths from the prior year, and the third consecutive annual drop, the longest sustained decline in decades.
But which strategies are contributing to this drop, and how can we sustain them? And what risks might persist and threaten progress?
What the Leading States Actually Did
The declines in Rhode Island, Virginia, West Virginia, and New York reflect years of deliberate investment in data systems and coordinated care delivery. They also offer a clear roadmap for what lagging states need to replicate.
- Rhode Island’s Governor’s Overdose Task Force, established in 2015, focused on four pillars: prevention, harm reduction, treatment engagement, and recovery support. By 2025, the state recorded its lowest overdose death count since before 2013, surpassing its own 2030 reduction goal five years early, with a 50% decline since 2022. A central driver was a commitment to real-time public health data dashboards that connected state agencies, community organizations, and academic research teams to shared overdose surveillance data, enabling faster identification of emerging hotspots and faster resource deployment.
- West Virginia, once the nation’s highest overdose death rate state, saw a 42% decline in 2024, driven in part by a multiagency collaboration between the state Board of Pharmacy and the Department of Health to maximize PDMP utilization, using prescription data for population-level surveillance and program evaluation, not just individual prescribing decisions.
- Across high-performing states, three patterns stand out consistently. PDMP integration moved from optional to mandatory, which led to a push in nearly 1/3 of all prescribers accessing the PDMP directly in EHR workflows rather than as a separate login. Medicaid expansion drove buprenorphine prescribing up: a September 2025 Health Affairs analysis found expansion states increased all-payer buprenorphine prescribing by more than 27%, while non-expansion states saw a 2.1% decline.
States that succeed have found ways to ensure information reaches clinicians in real time, at the moment of a clinical decision. Wider naloxone availability, expanded access to medications for opioid use disorder (MOUD), and increased PDMP utilization have all contributed to a shift that was far from guaranteed. Yet the need for sustained change remains a challenge, especially in areas with treatment deserts.
A Decline That Is Not Evenly Distributed
Seven states saw overdose deaths increase in 2025, including sharp spikes of more than 10% in Arizona, Colorado, and New Mexico. These are warning signs about where the next wave is building.
Geographic disparities in opioid treatment access are deepening. Research published in January 2026 documents what practitioners in these regions already know: rural communities face critical shortages of MOUD providers, with some areas classified as treatment deserts where evidence-based care is geographically inaccessible. In parts of Arizona, the average drive time to an opioid treatment program exceeds two hours.
Two other forces are also converging to put the national decline at risk. First, the illicit drug supply continues to shift in ways that outpace static intervention models. A federally funded toxicology lab identified 23 new substances in less than five months of 2026, nearly matching all of 2025’s full-year total of 27. Synthetic opioids far more potent than fentanyl are already appearing in street drug supplies, often without buyers’ knowledge.
Second, the funding infrastructure supporting naloxone distribution, care navigation, and community health workers is under significant pressure. Addiction treatment organizations in 2026 are navigating deep uncertainty about federal program support, creating gaps in the community-level response precisely when continuity matters most. When a rural community loses a single navigator or a PDMP-linked referral program, there is often nothing to backfill it.
What Falling-Behind States Can Do Now
The interventions that worked in leading states are replicable and available through existing federal funding mechanisms and technology infrastructure.
Mandating and integrating PDMP access within EHR workflows is the highest-leverage step available to most states. The CDC has identified real-time PDMP data and submission intervals of under 5 minutes as significantly more effective than delayed reporting, ensuring providers act on current information rather than prescription histories that are days old.
Expanding Medicaid coverage for MOUD and removing prior-authorization barriers to buprenorphine have demonstrated an outsized impact wherever implemented, addressing one of the most durable barriers to patients’ access to effective treatment.
For geographies where provider shortages make in-person care structurally inaccessible, technology-enabled navigation (such as care coordinators working from ADT alerts, PDMP risk flags, and proactive roster review) allows a limited workforce to reach a much larger population. Bridging that connectivity gap is where the next round of meaningful progress will come from.
Sustaining the Decline
The states that have seen the steepest overdose declines invested in proactive, coordinated care infrastructure: systems that could identify risk before the overdose, not only reverse one after it happened. Sustaining the national decline and extending it to communities currently moving in the wrong direction requires applying the same logic in areas with thin provider capacity, long drive times, and uncertain funding.
Technology-enabled care navigation, PDMP-integrated workflows, and unified behavioral and physical health visibility help scale improved outcomes in environments where there are limited resources. To learn more, visit Bamboo Bridge, or contact our team to discuss how Bamboo Health can support sustaining your organization’s care navigation strategy.
